

Newsletter dell'ARIC con informazioni su bandi, programmi e progetti di ricerca

[View this email in your browser](#)



## ResearchNews N. 29/2020

22 Dicembre 2020



HR EXCELLENCE IN RESEARCH  
CARTA EUROPEA DEI RICERCATORI

## BANDI E OPPORTUNITA'



### RHEUMATOID ARTHRITIS ITALIAN REAL WORLD EXPERIENCE

On 15<sup>th</sup> December Pfizer has published this Request for Proposal (RFP) on Real World Data (RWD) in Rheumatoid Arthritis (RA).

The intent of this RFP is to fund observational research projects in RA (mono or multicentric), with an exclusive focus on Real World Data (RWD) and Real world evidence (RWE), in relation to one or more of the following topics:

- Treat-to-Target strategies in RA patients treated with JAK inhibitors (JAKis)
- Efficacy and safety of treatment optimization with JAKis (e.g. monotherapy - in case of intolerance to methotrexate (MTX) or when MTX is inappropriate -, MTX and/or glucocorticoids (GCs) management)
- Treatment strategies: o temporary discontinuation, o switching from biological disease-modifying antirheumatic drugs (bDMARDs) to targeted synthetic disease-modifying antirheumatic drugs

**Subscribe****Past Issues****Translate ▼**

history of malignancies, high cardiovascular (CV) risk, interstitial lung disease (ILD)

- CV and venous thromboembolism (VTE) outcomes in RA patients on Tofacitinib compared with bDMARDs and/or other JAKis
- Response and safety signals in patient subtypes such as, but not limited to, patients:
  - o With Extra-articular manifestations
  - o over 65 years old vs younger
  - o ACPA and/or RF-positive vs negative
  - o With Early RA vs longstanding RA
- Tofacitinib, bDMARDs and/or other JAKis treatment persistence in RA patients (both monotherapy and combination therapy)
- RWE from RA patient perspectives on tofacitinib, including but not limited to
  - o efficacy profile (e.g. RAPID3, HAQ-DI, EQ5, SF36, etc.)
  - o time to onset of efficacy,
  - o patient satisfaction / adherence / compliance

Deadline: **18/02/2021**

More information at the link:

[GMG\\_2021-I&I-L\\_REALE2021-RhEumatoidArthritisItalianRealWorldExperience.pdf](#) (pfe-pfizercom-d8-prod.s3.amazonaws.com)



## **PFIZER - REQUEST OF PROPOSAL "INFLAMMATORY AND IMMUNE-MEDIATED DERMATOLOGIC DISORDERS"**

The intent of this Request for Proposal (RFP) is to support preclinical, clinical and outcomes research through a competitive grant program with the intent to increase medical knowledge in the diagnosis and management of inflammatory and immune-mediated dermatologic disorders.

Areas of Research Focus:

Mechanistic insights into the role of the JAK/STAT pathway in inflammatory dermatologic diseases

Pharmacogenomic studies in atopic dermatitis to identify potential responders to JAK inhibition, including skin of color

Unmet need and burden of disease of alopecia areata and vitiligo

Epidemiological studies in alopecia areata

Validation of AD disease severity measures in skin of color

Identification of inflammatory pathways related to the pathophysiology of alopecia areata and vitiligo

Identification of immunophenotypic differences in clinical course and treatment response of AD in skin of color

Deadline: **24/02/2021**



## **EURONANOMED - JOINT TRANSNATIONAL CALL FOR PROPOSAL FOR "EUROPEAN INNOVATIVE RESEARCH & TECHNOLOGICAL DEVELOPMENT PROJECTS IN NANOMEDICINE"**

EuroNanoMed (ENM) is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research and innovation programmes with the goal of creating and funding collaborative research and innovation projects that can convert research in nanotechnology into practical gains in medicine.

Funded themes:

1. Regenerative Medicine
2. Diagnostics
3. Targeted Delivery Systems
- 4.

Deadlines: fase 1 (pre-proposal) **21/01/2021**, fase 2 (full proposal) **10/06/2021**

More information at the link: <https://euronanomed.net/joint-calls/12th-joint-call-2021/>



## **NIH - NIA MULTI-SITE COVID-19 RELATED CLINICAL TRIAL IMPLEMENTATION GRANT ON AGING-RELATED TOPICS IN AT-RISK OLDER ADULT POPULATIONS**

This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19). Applications on the following priority topics are invited:

- Efficacy and safety of interventions that target aging-related biological mechanisms that may influence risk or severity of COVID-19 infection among at-risk older adults
- Efficacy and safety of preventive and treatment interventions in older patients with differing comorbid conditions that make them especially vulnerable to adverse outcomes of COVID-19

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

outcomes of COVID-19 infection in nursing homes or other residential settings serving at-risk older persons, including the development and testing of infection control training procedures for healthcare workers

- Rapid pragmatic trials in (at least two) health systems, nursing homes, or adult living facilities, ensuring replication across large pragmatic trial sites and leveraging electronic health records to promote quality improvement in physician, hospital, palliative care, and hospice practices to improve outcomes for older patients with COVID-19, especially those with cognitive impairment, Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD), or underlying comorbidities
- Trials in at-risk older adults age 65 and older for whom electronic medical records are available and long-term outcomes can be tracked, and in institutions serving those populations
- Trials in older adults with AD/ADRD, older adults from populations with NIH-defined health disparities, and/or other vulnerable populations (e.g. incarcerated, homeless, living in institutions)

Deadline: **01/02/2021**

More information at the link: <https://grants.nih.gov/grants/guide/pa-files/PA-20-234.html>




## ERA PER-MED - JOINT TRANSNATIONAL CALL 2021

To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 30 funding organisations have agreed to launch the fourth Joint Transnational Call for collaborative innovative research projects in PM.

The available budget for this call is 24 Mio € (approx.)

Deadline for preproposal: **4/3/2021** (17:00 CET)

Deadline for invited full-proposal: **17/6/2021** (17:00 CET)

More information: <http://www.erapermed.eu/joint-calls/joint-transnational-call-2021/>



RESEARCH & INNOVATION PROGRAMME  
ON RAW MATERIALS  
TO FOSTER CIRCULAR ECONOMY

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

The first joint call of the ERA-NET Cofund ERA-MIN3 will be officially launched on the **15th of January, 2021**, and will count with an indicative budget of **€19 Million**.

Deadline for pre-proposal: **1/4/2021**

Deadline for full proposal: **15/9/2021**

**More information:** [https://www.era-min.eu/sites/default/files/docs/1st\\_pre-announcement\\_era-min\\_joint\\_call\\_2021.pdf](https://www.era-min.eu/sites/default/files/docs/1st_pre-announcement_era-min_joint_call_2021.pdf); <https://www.era-min.eu/joint-call/era-min-joint-call-2021>



## EUROPEAN JOINT PROGRAMME ON RARE DISEASE (EJP RD) CALL FOR PROPOSAL 2021

Topic: Social sciences and Humanities Research to improve health care implementation and everyday life of people living with a rare disease

Research proposals should cover at least one of the following areas:

- Health & social care services research to improve patient and familial/household health outcomes
- Economic Impact of Rare diseases
- Psychological and Social Impact of Rare diseases
- Studies addressing the impact/burden of the delay in diagnosis and of the lack of therapeutic intervention.
- e-Health in rare diseases: Use of innovative technology systems for care practices in health and social services
- Development and enhancement of health outcomes research methods in rare diseases
- Effects of pandemic crisis and the global outbreak alert and response on the rare disease field, and the emergence of innovative care pathways in this regard.

Other research topics are possible as long as they focus on SSH research and are not in the excluded topics list.

Deadline for pre-proposal: **16/2/2021**

Deadline for full proposal: **15/6/2021**

More information: <https://www.ejprarediseases.org/index.php/announcement-jtc2021/>



## **MISE - BANDO DI FINANZIAMENTO DI PROGETTI DI RICERCA TECNOLOGICA - PIANO TRIENNALE DELLA RICERCA DI SISTEMA ELETTRICO NAZIONALE 2019-2021**

Il bando è pubblicato nell'ambito del Piano triennale della Ricerca di Sistema elettrico nazionale 2019-2021 e le proposte progettuali dovranno prevedere attività di ricerca industriale e/o di sviluppo sperimentale nei seguenti settori tecnologici:

- fotovoltaico ad alta efficienza;
- sistemi di accumulo, compresi elettrochimico e power to gas, e relative interfacce con le reti;
- efficienza energetica dei prodotti e dei processi industriali, così come identificati nel decreto direttoriale 9 agosto 2019

Deadline: **31/3/2021**

Maggiori dettagli: <https://www.mise.gov.it/index.php/it/normativa/notifiche-e-avvisi/2041785-bando-di-finanziamento-di-progetti-di-ricerca-tecnologica-piano-triennale-della-ricerca-di-sistema-elettrico-nazionale-2019-2021>



***L'Area Ricerca augura a voi e alle vostre famiglie un Sereno Natale e un buon Anno Nuovo***

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

---

*Copyright © 2019 Università di Udine - ARIC, All rights reserved.*

Ricevete questa mail in quanto docenti/ricercatori dell'Università degli Studi di Udine

**Our mailing address is:**

Università di Udine - ARIC

Via Mantica 31

Udine, Ud 33100

Italy

[Add us to your address book](#)

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#)

